Last update 20 Mar 2025

Traneurocin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
NEUROSIVIR
+ [2]
Target-
Action
stimulants
Mechanism
Neurogenesis stimulants
Therapeutic Areas
Nervous System Diseases
Active Indication
Alzheimer Disease
Inactive Indication
COVID-19Dementia, VascularLewy Body Disease+ [5]
Originator Organization
NeuroActiva, Inc.NeuroActiva, Inc.
Active Organization
Biomed Industries, Inc.NeuroActiva, Inc.NeuroActiva, Inc.
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

4
Clinical Trials associated with Traneurocin
NCT04452565
/ Unknown statusPhase 2/3
Randomized Controlled Phase 2/3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection
NCT04540185
/ Unknown statusPhase 3
A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for Prophylaxis and Treatment of Early Onset of Covid-19
NCT04480333
/ Unknown statusPhase 1
A Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy Volunteers
100 Clinical Results associated with Traneurocin
Login to view more data
100 Translational Medicine associated with Traneurocin
Login to view more data
100 Patents (Medical) associated with Traneurocin
Login to view more data
100 Deals associated with Traneurocin
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alzheimer DiseasePhase 3-
Biomed Industries, Inc.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03538522 (AAIC 12022 | AAIC 22022)
ManualManual
Phase 2
Alzheimer Disease
56
(xxiatggbgn) = NA-831 was well-tolerated at 30 mg/day for 24 weeks, and no serious adverse events were observed. cqvtesckgy (lcidcsaypn )
View more
Positive
20 Dec 2022
Placebo
AAIC2018
Not Applicable
Alzheimer Disease
32
Placebo
tvyenpvroy(mxmddvodcn) = duohyitlte yfaymbvwbo (yssdxzjmiy )
-
01 Jul 2018
tvyenpvroy(mxmddvodcn) = qfzxgcpqpb yfaymbvwbo (yssdxzjmiy )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free